116 related articles for article (PubMed ID: 22094668)
21. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
Batus M; Fidler MJ; Bonomi PD
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor mutations in lung cancer.
Sharma SV; Bell DW; Settleman J; Haber DA
Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
[TBL] [Abstract][Full Text] [Related]
23. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
Ou SH
Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
[TBL] [Abstract][Full Text] [Related]
24. Individualizing therapy for non-small-cell lung cancer: a paradigm shift from empiric to integrated decision-making.
Gandara DR; Lara PN; Mack P; Scagliotti G
Clin Lung Cancer; 2009 May; 10(3):148-50. PubMed ID: 19443333
[No Abstract] [Full Text] [Related]
25. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities.
da Cunha Santos G; Saieg MA; Geddie W; Leighl N
Cancer Cytopathol; 2011 Apr; 119(2):80-91. PubMed ID: 21400669
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapy for non-small cell lung cancer.
Jett JR; Carr LL
Am J Respir Crit Care Med; 2013 Oct; 188(8):907-12. PubMed ID: 23721055
[TBL] [Abstract][Full Text] [Related]
27. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
28. [Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer].
Zhou CC; Deng XF
Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb; 30(2):138-40. PubMed ID: 17445479
[No Abstract] [Full Text] [Related]
29. Novel molecular trends in the management of advanced non-small-cell lung cancer.
Metro G; Crinò L
Expert Rev Anticancer Ther; 2012 Jun; 12(6):729-32. PubMed ID: 22716489
[TBL] [Abstract][Full Text] [Related]
30. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
31. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.
Calvo E; Baselga J
J Clin Oncol; 2006 May; 24(14):2158-63. PubMed ID: 16682734
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapies and non-small-cell lung cancer: new developments.
Gridelli C
Curr Opin Oncol; 2007 Mar; 19(2):75-7. PubMed ID: 17272976
[No Abstract] [Full Text] [Related]
33. First-line crizotinib shows promise in patients with NSCLC.
Bagcchi S
Lancet Respir Med; 2015 Jan; 3(1):17. PubMed ID: 25497281
[No Abstract] [Full Text] [Related]
34. [A new target in non-small cell lung cancer: ROS1 fusion gene].
Cai WJ; Su B
Zhonghua Zhong Liu Za Zhi; 2013 Jan; 35(1):1-4. PubMed ID: 23648291
[No Abstract] [Full Text] [Related]
35. Discovery of drug resistance biomarker could improve cancer treatment.
Pharmacogenomics; 2013 Jan; 14(2):125. PubMed ID: 23447824
[No Abstract] [Full Text] [Related]
36. Oncologists push beyond new lung cancer genomic testing guidelines.
Garber K
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25677038
[No Abstract] [Full Text] [Related]
37. [About new treatments in thoracic oncology].
Couraud S
Rev Pneumol Clin; 2013 Apr; 69(2):63-4. PubMed ID: 23434002
[No Abstract] [Full Text] [Related]
38. Progress in research on screening and genetics in lung cancer.
Hirsch FR; Bunn PA
Lancet Respir Med; 2014 Jan; 2(1):19-21. PubMed ID: 24461890
[No Abstract] [Full Text] [Related]
39. Personalized medicine for non-small-cell lung cancer.
Kucherlapati R
Oncology (Williston Park); 2010 Apr; 24(5):399-400. PubMed ID: 20480736
[No Abstract] [Full Text] [Related]
40. Unlocking the biological clues of lung cancer.
Hanna N
J Thorac Oncol; 2008 Aug; 3(8):809-10. PubMed ID: 18670296
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]